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Abstract
Background: Medical abortion with mifepristone and misoprostol was introduced in
Norway in 1998, and since then there has been an almost complete change from pre-
dominantly surgical to medical abortions. We aimed to describe the medical abortion im-
plementation process, and to compare characteristics of women obtaining medical and
surgical abortion.
Methods: Information from all departments of obstetrics and gynaecology in Norway on
the time of implementation of medical abortion and abortion procedures in use up to 12
weeks of gestation was assessed by surveys in 2008 and 2012. We also analysed data
from the National Abortion Registry comprising 223 692 women requesting abortion up
to 12 weeks of gestation during 1998–2013.
Results: In 2012, all hospitals offered medical abortion, 84.4% offered medical abortion
at 9–12 weeks of gestation and 92.1% offered home administration of misoprostol. The
use of medical abortion increased from 5.9% of all abortions in 1998 to 82.1% in 2013.
Compared with women having a surgical abortion, women obtaining medical abortion
had higher odds for undergoing an abortion at 4–6 weeks (adjusted OR 2.33; 95% confi-
dence interval 2.28-2.38). Waiting time between registered request for an abortion until
termination was reduced from 11.3 days in 1998 to 7.3 days in 2013.
Conclusions: Norwegian women have gained access to more treatment modalities and
simplified protocols for medical abortion. At the same time they obtained abortions at an
earlier gestational age and the waiting time has been reduced.
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Introduction
Termination of pregnancy is one of the most common proced-
ures in reproductive health. At the same time it is one of the
more controversial and politically contentious procedures in
medicine.1 The abortion rate in the world is declining, but
the proportion of unsafe abortions is increasing.2 In Norway
the abortion rate has been relatively stable, ranging from
12.5–14.5 per 1000 women aged 15–49 between 1995 and
2013 (14).3 Misoprostol used for clandestine abortions is
associated with lower risk of maternal mortality and morbid-
ity than unsafe surgical abortions, but there is a lack of know-
ledge about the correct use for pregnancy termination.2
Increased knowledge and the combined use of mifepristone
and misoprostol could help reduce maternal deaths, particu-
larly in areas with limited numbers of health professionals and
low access to health services in both legal and illegal settings.
Norway began offering medical abortion with mifepris-
tone and misoprostol in 1998. Due to a dispute in
Parliament over a planned clinical trial of mifepristone in
1989 (Figure 1), the pharmaceutical company producing
mifepristone withdrew their application to register mifepris-
tone in Norway.4 In 1998, mifepristone was introduced in
Norway as a drug with exemption from registration.
Mifepristone was registered for use in Norway in 2001.5
Norway has a public health system and every department of
obstetrics and gynaecology in the country is obliged to per-
form abortions completely free of charge. Only physicians
are entitled to perform abortions, but delegation to other
health professionals under supervision is not prohibited.6
Doctors always undertake surgical abortions, whereas med-
ical abortions very often are allocated to nurses. No abor-
tions are performed outside the public health system.
Since the registration of mifepristone in France in 1988,
medical abortion with mifepristone and misoprostol has
been available, is thoroughly documented for use up to 9
weeks of gestation and was in 2016 approved for use up to
70 days by the US Food and Drug Administration.7,8 Over
the past 25 years, the treatment procedures have been modi-
fied and introduced for use in both late first trimester and
second trimester abortions, and it has become available in a
growing number of countries.9–11 Medical abortion requires
fewer human and economic resources and can be more cost-
effective than surgical abortion, especially if the number of
visits for treatment and follow-up are reduced.12,13 Medical
abortion was included in the Norwegian national guidelines
for abortion treatment up to 9 weeks of gestation in 2004.
The recommended treatment protocol was 200–600 mg
mifepristone, admission to hospital and administration of
800 mg misoprostol after 42–48 h.14 In 2009, the guidelines
were altered to recommend self-administration of misopros-
tol vaginally at home and to extend the gestational limit of
medical abortion from 9 to 12 weeks of gestation.15
Some critics have feared that increased access to med-
ical abortion would increase the number of abortions.4
From the introduction of medical abortion with mife-
pristone and misoprostol in Norway, there has been an al-
most complete change in abortion procedures from close
to 100% surgical abortions in 1997 to 82.1% of all abor-
tions being performed medically in 2013.3 Approximately
95% of all abortions are performed within 12 weeks of
gestation.3 There is some knowledge on why some women
prefer medical abortion whereas others opt for surgical
abortion,16 but little is known about possible differences in
characteristics between these two populations in Norway.
This study describes the implementation process of med-
ical abortion in Norway over the first 15 years after the intro-
duction in 1998 (Figure 1) and the current abortion practice
at Norwegian hospitals based on a facility survey sent to all
hospitals providing abortion services at the two time points,
2008 and 2012. Data from the Abortion Registry are used to
describe the proportion of abortions that were undertaken
medically or surgically from 1998 to 2013 and to compare
the characteristics of women who chose medical versus surgi-
cal abortions. We also evaluated if the almost complete
change in abortion practices influenced the waiting time from
request for an abortion until termination.
Methods
Study design and material
First, this is a review of the practice and implementation of
medical abortion in Norway through a survey sent to all
Key messages
• There has been an almost complete change in abortion treatment in Norway from predominantly surgical abortion in
1998 to medical abortion in 2013.
• Norwegian hospitals follow national and international guidelines.
• After the introduction of medical abortion, women access abortion at an earlier gestational age and waiting time
from the request of an abortion to termination has been reduced.
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hospitals offering termination of pregnancy at two time
points, in 2008 and 2012. Second, it is a study of 223 692
women in the Abortion Registry who requested abortion
and terminated a pregnancy up to 12 weeks of gestation in
the years 1998 to 2013.
Hospital surveys
In 2008, a questionnaire was elaborated by the research
group and sent by mail to all 40 departments of obstet-
rics and gynaecology performing abortions in Norway
[helseadresser.no] with the purpose of mapping the preva-
lence and distribution of medical abortion and treatment
protocols. The survey was repeated in 2012 after a rapid
increase in medical abortion was reported by the Abortion
Registry.3 Due to merging of closely located clinics, the
number of hospitals was reduced to 38. Information about
the existing treatment portfolio was obtained through the
questions: do you offer medical abortion up to 9 weeks
of gestation, medical abortion with home administration
of misoprostol, and medical abortion between 9 to 12
weeks of gestation; and in which years were the different
treatment options introduced. In addition, dosages of mife-
pristone (200 mg, 400 mg, or 600 mg), route of adminis-
tration of misoprostol (oral or vaginal), and follow-up
regimen used ([serum-human chorionic gonadotropin
(s-hCG); urine-hCG; ultrasound/clinical or no control]
were requested.
Abortion Registry
The Abortion Registry was established in 1979 and is a
population-based, de-identified registry. Data are recorded
in a standard form using check boxes with specific alterna-
tives, at the hospital performing the abortion, and are then
sent to the registry. The woman’s name and personal iden-
tification number are removed before the form leaves the
hospital. Hence, it is not possible to link the registry to
other health registries nor to follow one particular wom-
an’s abortion history.
The following variables in the Abortion Registry were
available for this study: year of termination, year of birth,
age, marital status (married, cohabiting, single, divorced/
widowed, not registered); employment status (full-time
and studying, full-time, part-time and studying, part-time
and applying for jobs, part-time and on social welfare,
part-time, student, unemployed, social welfare, other);
educational level (primary, secondary, college/university,
other); previous pregnancies; number of children; previous
terminations; date of registered request for abortion and
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The standard abortion form has changed three times
during this time period, in 1995, 1999 and 2006. Medical
abortion as a specific method of termination was first
included in 2006. In the forms used before 2006, one
could register ‘injection of abortifacient’ or ‘local appli-
cation of prostaglandin’. For data collected before 2006,
the registry has defined medical abortion as the use of one
of these methods, and at the same time the absence of
surgery. Information on educational level was also
first introduced in 2006. Information on whether miso-
prostol has been administered in hospital or outside hos-
pital, mifepristone dosage, route of administration of
misoprostol and control regimen are not included in the
form.
A total of 311 (0.1%) women lacked information on
method and were excluded from the analyses of medical
and surgical abortion. Data with extreme measures were
excluded from the analyses: gestational age below 4 weeks
of gestation (342); number of previously born children
higher than 12 (3); women older than 54 years (2); and
number of previous abortions above 12 (11). Abortions on
request that were undergone after 12 weeks of gestation
were also excluded.
Statistical analyses
All abortions were subdivided and compared according to
method used (medical, surgical). Frequencies, univariate
and multivariate logistic regression analyses were used to
compare medical and surgical abortions, according to
characteristics of the study population (woman’s age, ges-
tational age, previous abortions, parity, level of education,
occupational status and marital status). We adjusted for
woman’s age, gestational age and year of the abortion in
multivariable logistic regressions comparing characteristics
of women undergoing medical versus surgical abortions.
The analyses were performed using Statistical Package for
Social Sciences 20 (SPSS) and R.
Ethical approval
The Committee for Medical and Health Research Ethics,
Western Norway (number 2009/738) and the Norwegian




Response rates for the two surveys, performed in 2008 and
2012, were both 100%. The surveys revealed an increase
in the percentage of hospitals in Norway offering medical
abortion, from nil in 1997 to 50% in 2001 and 100% in
2010. In 2012, a total of 84.4% offered medical abortion
at 9–12 weeks of gestation and 92.1% of all hospitals
offered home administration of misoprostol (Figure 2).
Table 1 demonstrates the different treatment practices in
the country. The most frequent mifepristone dosage ad-
ministered was 200 mg (83.3% in 2008 and 94.7% in
2012). Two (5.3%) hospitals chose 400 mg of mifepristone
for their medical abortions and one (3.0%) hospital used
600 mg for medical abortion at 9–12 weeks of gestation in
2012. The vaginal route was the most common administra-
tion method for misoprostol both in 2008 (85.7%) and in
2012 (94.2%). For home use of misoprostol, the oral route
was chosen by 14.3% of the hospitals in 2012. The use of
u-hCG as follow-up procedure increased between 2008
Figure 2. Percentage of hospitals offering medical abortion treatments in 1998-2012. Based on data from the 2012 survey.
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and 2012, and was in 2012 the most frequently used
method (45.5-51.4%), dependent on protocol.
Abortion Registry
The percentage of abortions performed medically with mife-
pristone and misoprostol increased from 5.9% of all abortions
in 1998 to 82.1% in 2013 (Figure 3), and the percentage of
all abortions undertaken within 9 weeks of gestation increased
from 44.0% in 1998 to 77.8% in 2013. The percentage of re-
quests for an abortion that ended in a termination decreased
steadily from 92.3% in 1998 to 88.5% in 2013.
A comparison of medical and surgical abortion accord-
ing to characteristics of the study population is shown in
Table 2. There was a higher number of women using a
medical approach to a termination under 7 weeks of
Table 1. Description of treatment methods for medical abortion in Norway, 2008 and 2012




up to 63 days of gestation
9-12 weeks of gestation
in hospital
Clinics providing abortion 2008 2012 2008 2012 2008 2012
N ¼ 40 (%) N ¼ 38 (%) N ¼ 40 (%) N ¼ 38 (%) N ¼ 40 (%) N ¼ 38 (%)
Clinics offering
medical abortion
36 (90) 38 (100) 9 (22.5) 35 (92.1) 7 (17.5) 32 (84.2)
missing 0 0 0 0 0 2
Mifepristone dose 36 38 9 35 7 33
200 mg 30 (83.3) 36 (94.7) 8 (88.9) 33 (94.2) 7 (100) 31 (93.9)
400 mg 2 (5.6) 2 (5.3) 1 (11.1) 2 (5.8) 0 1 (3.0)
600 mg 4 (11.1) 0 0 0 0 1 (3.0)
missing 0 0 0 0 0 5
Misoprostol route of
administration
34 38 8 35 7 32
vaginal 32 (94.1) 32 (94.2) 8 (100) 30 (85.7) 7 (100) 29 (90.6)
oral 2 (5.9) 6 (5.8) 0 5 (14.3) 0 3 (9.4)
missing 2 0 1 0 0 0
Control regimen 35 38 9 35 6 33
u-hCG 10 (28.6) 19 (50.0) 3 (33.3) 18 (51.4) 3 (50.0) 15 (45.5)
s-hCG 9 (25.7) 13 (34.2) 5 (55.6) 13 (37.1) 2 (33.3) 9 (27.3)
ultrasound 12 (34.3) 4 (10.5) 1 (11.1) 2 (5.7) 1 (17.7) 9 (27.3)
no control 4 (114) 2 (53) 0 2 (57) 0 0
missing 1 0 0 0 1 5
Figure 3. Percentage of medical and surgical abortions 1998-2013, based on 223 692 abortions.
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gestation than women having a surgical abortion [adjusted
odds ratio (OR) 2.11; 95% confidence interval (CI) 2.06-
2.16), and a slightly reduced likelihood of undergoing a
medical abortion among women with previous abortion
experience (adjusted OR 0.87; 95% CI 0.85-0.90). The
odds for undergoing a medical procedure in comparison
Table 2. Frequencies, crude and adjusted odds ratios (ORs) of medical in comparison with surgical abortion according to char-
acteristics of the study population: 223 692 women requesting abortion up to 12 weeks of gestation in Norway, 1998-20131
Medical (n ¼ 100605) Surgical (n ¼ 122776) Crude Adjusted2
OR (95% CI) OR (95% CI)
N % Median (range) N % Median (range)
Age (years) 26 (12-52) 26 (12-51)
 19 13596 13.5 21161 17.2 0.74 (0.72-0.76) 0.85 (0.82-0.87)
20-24 28209 28.0 32542 26.5 1.00 Reference 1.00 Reference
25-29 22811 22.7 26259 21.4 1.00 (0.98-1.03) 0.99 (0.97-1.02)
30-34 17744 17.6 21819 17.8 0.94 (0.91-0.96) 0.98 (0.95-1.01)
35-39 12911 12.8 15139 12.3 0.98 (0.96-1.01) 0.99 (0.96-1.03)
40-44 4944 4.9 5336 4.3 1.07 (1.03-1.11) 1.00 (0.95-1.05)
 45 384 0.4 408 0.3 1.09 (0.94-1.25) 0.96 (0.81-1.15)
Missing 6 0 112 0.1
Gestational age (weeks) 7 (4-12) 8 (4-12)
4-6 41874 41.6 20522 16.7 2.34 (2.29-2.39) 2.11 (2.06-2.16)
7-8 46682 46.4 53454 43.5 1.00 Reference 1.00 Reference
9-10 8893 8.8 36304 29.6 0.28 (0.27-0.29) 0.22 (0.22-0.23)
11-12 2881 2.9 12429 10.1 0.27 (0.25-0.28) 0.19 (0.18-0.20)
Missing 275 0.3 67 0
Previous abortions 0 (0-11) 0 (0-12)
0 54750 54.4 55388 45.1 1.00 Reference 1.00 Reference
1 23859 23.7 29382 23.9 0.82 (0.80-0.84) 0.87 (0.85-0.90)
 2 10771 10.7 13200 10.8 0.83 (0.80-0.85) 0.74 (0.71-0.76)
Missing 11225 11.2 24806 20.2
Parity 1 (0-11) 1 (0-10)
0 42661 42.4 44765 36.5 1.00 Reference 1.00 Reference
1 18728 18.6 23021 18.8 0.85 (0.83-0.87) 0.91 (0.88-0.94)
2 18869 18.8 22469 18.3 0.88 (0.86-0.90) 0.89 (0.86-0.92)
 3 10555 10.5 13735 11.2 0.81 (0.78-0.83) 0.84 (0.81-0.88)
Missing 9792 9.7 18786 15.3
Level of education3
Elementary/secondary school 13001 12.9 8428 6.9 0.74 (0.71-0.76) 0.78 (0.75-0.81)
High school/upper secondary 34200 34.0 16315 13.3 1.00 Reference 1.00 Reference
Collage/universityMissing 19176 19.1 7074 5.8 1.29 (1.25-1.34) 1.19 (1.15-1.24)
34228 34.0 90959 74.1
Occupational status
Full time 41499 41.2 46920 38.2 1.00 Reference 1.00 Reference
Part time 15413 15.3 14781 12.0 1.18 (1.15-1.21) 1.18 (1.15-1.21)
Student 21762 21.6 28043 22.8 0.88 (0.86-0.90) 0.88 (0.86-0.90)
Out of work 6352 6.3 8675 7.0 0.83 (0.80-0.86) 0.83 (0.80-0.86)
Other 9248 9.2 17321 14.1 0.60 (0.59-0.62) 0.60 (0.59-0.62)
Missing 6331 6.3 7036 5.7
Marital status
Married 18193 18.1 23396 19.1 0.94 (0.92-0.96) 0.89 (0.86-0.92)
Cohabiting 26388 26.2 28978 23.6 1.10 (1.07-1.12) 1.09 (1.07-1.12)
Single 47058 46.8 56667 46.2 1.00 Reference 1.00 Reference
Divorced/widowed 4270 4.2 5436 4.4 0.95 (0.91-0.99) 0.96 (0.91-1.02)
Missing 4696 4.7 8299 6.8
1A total of 311 (0.1%) of the women had no record of method.
2Adjusted for gestational age, the woman’s age and year of the abortion.
3Level of education was not registered prior to 2006.
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with surgery increased with increasing level of education
and decreased with increasing parity (Table 2). There were
no differences in age, occupational or marital status be-
tween the two groups.
The mean number of waiting days between registered
requests for abortion until termination decreased from
11.3 in 1998 to 7.3 days in 2013. The decline in waiting
days for medical abortion was from 12.3 days in 1998 to
6.6 days in 2013, in comparison with a decline from 11.3
to 10.1 days for surgical termination, respectively.
Discussion
To the best of our knowledge, this is the first complete coun-
trywide report on all registered legal abortions from a
15-year introductory period of medical abortion. We present
full figures from all hospitals performing abortions and all
abortions conducted during this period. Norway experienced
an almost complete change in the use of abortion methods
from surgical to medical abortion. In the same period, an
increasing percentage of all abortions were performed within
9 weeks of gestation and there was a reduction in waiting
time from the request for an abortion to termination.
The percentage of all abortions undergone medically
increased from 5.9% to 82.1% between 1998 and 2013. In
the same time period, the number of abortions remained
stable with a slight decrease in abortion rates.3 Thus, in
spite of concerns that a non-surgical method would in-
crease the total number of abortions, this did not happen.
A similar trend in use of medical abortion and abortion
rates are found in the other Scandinavian countries and
Scotland, where most abortions are done within the
National Health Services (NHS).17,18 We identified an in-
crease in abortions undergone before 9 weeks of gestation.
This is also in line with changes observed in Scotland,
Portugal and other Scandinavian countries.17–19 The ma-
jority of hospitals in our study followed recommended
guidelines for mifepristone dose and vaginal administra-
tion of misoprostol for all gestational ages. In contrast, a
similar development could not be revealed in a national
Dutch study where 45.7% of the institutions used either
misoprostol or mifepristone as a single agent for termin-
ation of pregnancy.20
After 2008, the Abortion Registry reported on a rapid
increase in the percentage of abortions undergone medic-
ally.3 This prompted the repeat survey in 2012 where we
found a rapid increase in the percentage of all hospitals
offering home administration of misoprostol and med-
ical abortion at 9–12 weeks after 2008 (Figure 2).
Subsequently, the percentage of all abortions performed
medically exceeded 50% (Figure 3). The increased use of
medical abortion followed the rapid scaling up of access to
home administration of misoprostol. Since most women
prefer one single visit when having an abortion, the intro-
duction of home administration of misoprostol with the
possibility of one single consultation could have been an
important factor.21,22 On the other hand, experience with
medical abortion had accumulated in Norway by 2008.
Medical abortion requires fewer resources, is more cost-
efficient and enables re-allocation of services to other pa-
tient groups. This makes it a good alternative to surgical
abortion for the hospitals.12,13 The annual report from the
Abortion Registry for 2015 describes a frequent use of
medical abortion (range 60.9-100%) in Norwegian hos-
pitals.3 The increase could be driven by both women’s and
provider preference. In places where unsafe abortions are
abundant and health services and personnel are lacking,
these aspects make medical abortion particularly import-
ant in increasing access to abortion.
In our surveys we found u-hCG tests for follow-up after
abortion to be the most frequently used method in
Norway. The surveys did not differentiate between low-
and high-sensitive u-hCG tests nor included information
on at what time follow-up was planned. Most medical
abortion protocols regularly include a follow-up proced-
ure. Several studies have found self-assessment and u-hCG
in combination with a telephone interview to be a good al-
ternative to s-hCG and ultrasound, as these simplify access
and reduce the resources needed.13,23,24 Self-assessment
combined with u-hCG is another promising approach, but
still there is a need for more sensitive and simpler tests to
reduce errors both in use and in interpretation of results.13
A reduced waiting time from 11.3 days in 1998 to 7.3
days in 2013 between a registered request for an abortion
to having the abortion was found. A study from the UK has
earlier retrieved a similar reduction in waiting time after
introduction of medical abortion.25 Several countries have
included compulsory waiting time in their abortion legisla-
tion under the argument that women ideally should have a
window to reconsider.26,27 The percentage of requests
being provided dropped from 92.3% in 1998 to 88.5% in
2013, whereas access to abortion was not reduced in the
same period. This reduction indicates that women are get-
ting enough time to re-evaluate their decisions.
In our study, women who underwent medical abortion
had a higher level of education than those treated with sur-
gical abortion. This is in line with other studies.28,29,30
Unfortunately, educational attainment was not registered
before 2006, with a high percentage of missing data in our
material as a result.
The major strengths of this study are the population-
based design comprising all abortions conducted in
Norway during 1998–2013, and a 100% response rate
in surveys from all the hospitals performing abortions in
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Norway. There might be a bias in recalling exactly when
the hospitals implemented medical abortion for the period
1998–2008. The number of clinics registered as performing
the different treatments in 2008 and 2012, on the other
hand, should not be subject to error. The types of variables
recorded in the Abortion Registry are fairly similar over
the years. Since information is de-identified, data quality
control is not possible through linkage of the registry with
other databases or studies. On the other hand, the
Abortion Registry shares data management personnel, rou-
tines and strategies with the Norwegian Medical Birth
Registry, a registry that through multiple validation studies
has been found to have high validity of data.31,32 As infor-
mation on previous abortions and deliveries, education
level, marital status and employment status are self-
reported parameters, the likelihood of information bias
must be taken into account when interpreting the results.
Possible stigma could influence the women’s information.
The registry has also had a delay in including changes in
abortion practice into their standard registration form. We
chose to use two different data sources to try to broaden
the information about access and quality of medical abor-
tion care beyond what was available from only one source.
By using two different sources we obtained information on
both a population and an institutional level. We found that
the two different data sources complemented each other in
describing and explaining the implementation process.
Large data registries like the Abortion Registry are very
often delayed in including new clinical treatment options
into their checkboxes. This is for instance the case regard-
ing home administration of misoprostol in Norway.
Without the facility survey, the role of home administra-
tion of misoprostol could not have been addressed in this
study. Neither does the Abortion Registry include informa-
tion on follow-up procedures after an abortion.
Our study revealed that Norwegian hospitals offer a var-
iety of different treatment protocols for medical abortion,
anchored in international guidelines. There seems to be a
trend towards simplification of the treatment process. The
major findings after the introduction of medical abortion
have been access to abortion at an earlier gestational age,
and reduced waiting time for women. Medical abortion
needs fewer resources than surgical abortion and, as a con-
sequence of the shift in treatment, local and national health
services have been able to release capacity that could be
reallocated to other treatment groups without compromis-
ing the needs of women with unwanted pregnancies.
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